Consequently, AML with FLT3-ITD (in the absence of other adverse-risk genetic lesions) is now classified as intermediate risk, irrespective of the allelic ratio or the presence of an NPM1 mutation [13]. The gene discussed is NPM1; the disease is acute myeloid leukemia.